These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36947202)

  • 1. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
    Tatarczuch M; Waltham M; Shortt J; Polekhina G; Hawkes EA; Ho SJ; Trotman J; Brasacchio D; Co M; Li J; Ramakrishnan V; Dunne K; Opat SS; Gregory GP
    Blood Adv; 2023 Jul; 7(14):3531-3539. PubMed ID: 36947202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
    Opat S; Tedeschi A; Hu B; Linton KM; McKay P; Leitch S; Coleman M; Zinzani PL; Jin J; Sun M; Sobieraj-Teague M; Browett P; Ke X; Thieblemont C; Ardeshna K; Bijou F; Walker P; Hawkes EA; Ho SJ; Zhou K; Liang Z; Xu J; Tankersley C; Delarue R; Co M; Trotman J
    Blood Adv; 2023 Nov; 7(22):6801-6811. PubMed ID: 37682792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.
    Johansson P; Klein-Hitpass L; Grabellus F; Arnold G; Klapper W; Pförtner R; Dührsen U; Eckstein A; Dürig J; Küppers R
    Oncotarget; 2016 Sep; 7(38):62627-62639. PubMed ID: 27566587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.
    Vela V; Juskevicius D; Gerlach MM; Meyer P; Graber A; Cathomas G; Dirnhofer S; Tzankov A
    Hematol Oncol; 2020 Aug; 38(3):284-292. PubMed ID: 32012328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.
    Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH
    Oncotarget; 2017 Mar; 8(10):17038-17049. PubMed ID: 28152507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
    Opat S; Tedeschi A; Linton K; McKay P; Hu B; Chan H; Jin J; Sobieraj-Teague M; Zinzani PL; Coleman M; Thieblemont C; Browett P; Ke X; Sun M; Marcus R; Portell CA; Ardeshna K; Bijou F; Walker P; Hawkes EA; Mapp S; Ho SJ; Talaulikar D; Zhou KS; Co M; Li X; Zhou W; Cappellini M; Tankersley C; Huang J; Trotman J
    Clin Cancer Res; 2021 Dec; 27(23):6323-6332. PubMed ID: 34526366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exome sequencing identifies recurrent
    Jallades L; Baseggio L; Sujobert P; Huet S; Chabane K; Callet-Bauchu E; Verney A; Hayette S; Desvignes JP; Salgado D; Levy N; Béroud C; Felman P; Berger F; Magaud JP; Genestier L; Salles G; Traverse-Glehen A
    Haematologica; 2017 Oct; 102(10):1758-1766. PubMed ID: 28751561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement.
    Hyeon J; Lee B; Shin SH; Yoo HY; Kim SJ; Kim WS; Park WY; Ko YH
    Mod Pathol; 2018 Sep; 31(9):1418-1428. PubMed ID: 29765142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.
    Vela V; Juskevicius D; Dirnhofer S; Menter T; Tzankov A
    Virchows Arch; 2022 Feb; 480(2):403-413. PubMed ID: 34494161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.
    Martínez N; Almaraz C; Vaqué JP; Varela I; Derdak S; Beltran S; Mollejo M; Campos-Martin Y; Agueda L; Rinaldi A; Kwee I; Gut M; Blanc J; Oscier D; Strefford JC; Martinez-Lopez J; Salar A; Sole F; Rodriguez-Peralto JL; Diez-Tascón C; García JF; Fraga M; Sebastián E; Alvés J; Menárguez J; González-Carreró J; Casado LF; Bayes M; Bertoni F; Gut I; Piris MA
    Leukemia; 2014 Jun; 28(6):1334-40. PubMed ID: 24296945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
    Phillips T; Chan H; Tam CS; Tedeschi A; Johnston P; Oh SY; Opat S; Eom HS; Allewelt H; Stern JC; Tan Z; Novotny W; Huang J; Trotman J
    Blood Adv; 2022 Jun; 6(11):3472-3479. PubMed ID: 35390135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
    Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
    Martinez-Lopez A; Curiel-Olmo S; Mollejo M; Cereceda L; Martinez N; Montes-Moreno S; Almaraz C; Revert JB; Piris MA
    Am J Surg Pathol; 2015 May; 39(5):644-51. PubMed ID: 25723115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
    Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
    Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.
    Peveling-Oberhag J; Wolters F; Döring C; Walter D; Sellmann L; Scholtysik R; Lucioni M; Schubach M; Paulli M; Biskup S; Zeuzem S; Küppers R; Hansmann ML
    BMC Cancer; 2015 Oct; 15():773. PubMed ID: 26498442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
    Hunter ZR; Xu L; Tsakmaklis N; Demos MG; Kofides A; Jimenez C; Chan GG; Chen J; Liu X; Munshi M; Gustine J; Meid K; Patterson CJ; Yang G; Dubeau T; Samur MK; Castillo JJ; Anderson KC; Munshi NC; Treon SP
    Blood Adv; 2018 Nov; 2(21):2937-2946. PubMed ID: 30401751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.
    van den Brand M; Rijntjes J; Hebeda KM; Menting L; Bregitha CV; Stevens WB; van der Velden WJ; Tops BB; van Krieken JH; Groenen PJ
    Histopathology; 2017 Jan; 70(2):174-184. PubMed ID: 27297871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.
    Parry M; Rose-Zerilli MJ; Ljungström V; Gibson J; Wang J; Walewska R; Parker H; Parker A; Davis Z; Gardiner A; McIver-Brown N; Kalpadakis C; Xochelli A; Anagnostopoulos A; Fazi C; de Castro DG; Dearden C; Pratt G; Rosenquist R; Ashton-Key M; Forconi F; Collins A; Ghia P; Matutes E; Pangalis G; Stamatopoulos K; Oscier D; Strefford JC
    Clin Cancer Res; 2015 Sep; 21(18):4174-4183. PubMed ID: 25779943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.